DELOR 0.05% Cream Price, Uses, Alternatives, Dose, and more in UAE 2023
DELOR 0.05% Cream
Drug name DELOR 0.05%
Active substance Clobetasol propionate
Size : 25g Collapsible Tube
Company : PHARMA INTERNATIONAL CO.
Uploaded By : Admin
ٍ Visits : 350 visit
Welcome to Dwaey, specifically on DELOR 0.05% Cream page.
This medicine contains an important and useful components, as it consists of Clobetasol propionate.
DELOR 0.05% is available in the market in concentration 0.5mg/g and in the form of Cream.
PHARMA INTERNATIONAL CO. is the producer of DELOR 0.05% and it is imported from JORDAN.
The most popular alternatives of DELOR 0.05% are listed downward .
Lets know how to use DELOR 0.05% Cream
Childn <12 yrs. Long-term treatment of ulcerative conditions, rosacea, pruritus; It is contraindicated in rosacea, acne vulgaris, perioral dermatitis, primary cutaneous viral infections (eg. herpes simplex, chickenpox), otitis externa with a perforated eardrum, hypersensitivity to the preparations. Scalp application is contraindicated in infection of the scalp.
Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur readily even without occlusion. If used in childhood, or on the face, courses should be limited to 5 days and occlusion should not be used. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye. If used in psoriasis careful patient supervision is important. Scalp Application: Keep away from eye. Flammable. Do not use or dry the hair near a fire or flame. Scalp Shampoo: Do not use on areas other than the scalp. Keep away from eye. Lactation: Excretion in milk unknown; use with caution
Clobetasol is a very potent corticosteroid used in short-term treatment of various inflammatory skin conditions. Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; and reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation.
Increased systemic exposure w/ CYP3A4 inhibitors (eg ritonavir & itraconazole).